Key Developments: Catalyst Pharmaceutical Partners Inc (CPRX.O)

CPRX.O on Consolidated Issue listed on NASDAQ Capital Market

2.63USD
21 Nov 2014
Price Change (% chg)

$-0.03 (-1.13%)
Prev Close
$2.66
Open
$2.69
Day's High
$2.69
Day's Low
$2.60
Volume
278,715
Avg. Vol
1,420,648
52-wk High
$3.49
52-wk Low
$1.65

Search Stocks

Latest Key Developments (Source: Significant Developments)

Catalyst Pharmaceutical Partners Inc Closes Previously Announced $15.1 Million Registered Direct Offering
Tuesday, 10 Sep 2013 11:52am EDT 

Catalyst Pharmaceutical Partners Inc announced that it has closed its previously announced offering of 8.8 million shares of its common stock in a registered direct public offering. The offering price was $1.72 per share, resulting in gross proceeds of approximately $15.1 million. Roth Capital Partners acted as the exclusive placement agent for the offering and Aegis Capital Corp., Maxim Group LLC and H.C. Wainwright & Co. acted as financial advisers with respect to the offering.  Full Article

Catalyst Pharmaceutical Partners Inc Announces Offering Of Shares - Form 8-K
Thursday, 5 Sep 2013 09:16am EDT 

Catalyst Pharmaceutical Partners Inc reported in its Form 8-K that it has entered into Subscription Agreements (collectively, the Subscription Agreement) with investors who agreed to purchase an aggregate of 8,800,000 shares (the Shares) of the Company’s common stock, par value $0.001 per share for a purchase price of $1.72 per Share, or an aggregate of $15.1 million in gross proceeds. Roth Capital Partners, LLC (“Roth”) acted as Placement Agent for the offering of the Shares (the Offering). Further, Aegis Capital Corporation, Maxim Group LLC and H.C. Wainright & Co. acted as financial advisors in connection with the offering. The closing of the Offering is expected to take place on September 10, 2013, subject to the satisfaction of customary closing conditions.  Full Article

Catalyst Pharmaceutical Partners Inc Receives Breakthrough Therapy Designation From FDA For Firdapse For Treatment Of LEMS
Tuesday, 27 Aug 2013 08:03am EDT 

Catalyst Pharmaceutical Partners Inc announced that investigational product Firdapse (amifampridine phosphate) has received Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for the symptomatic treatment of patients with Lambert-Eaton Myasthenic Syndrome (LEMS). Firdapse is Catalyst's investigational therapy that is being evaluated for the treatment of the debilitating symptoms associated with LEMS, including muscle weakness.  Full Article

Catalyst Pharmaceutical Partners Inc Announces Recommendation Of Data Monitoring Committee For Pivotal Phase lll Clinical Trial For Firdapse
Wednesday, 27 Mar 2013 08:03am EDT 

Catalyst Pharmaceutical Partners Inc announced that on March 25, 2013, the independent Data Monitoring Committee (DMC) overseeing the Company's ongoing pivotal Phase III clinical trial in the United States and Europe evaluating Firdapse for the treatment of Lambert-Easton Myasthenic Syndrome (LEMS) recommended that the Company continue the trial as planned based on the committee's review of safety and clinical data from the trial. on March 25, 2013, the independent Data Monitoring Committee (DMC) overseeing the Company's ongoing pivotal Phase III clinical trial in the United States and Europe evaluating Firdapse for the treatment of Lambert-Easton Myasthenic Syndrome (LEMS) recommended that the Company continue the trial as planned based on the committee's review of safety and clinical data from the trial. The DMC considers study-specific data, as well as relevant background knowledge about the disease, test agent or patient population under study. The Firdapse Phase III clinical trial is designed as a randomized, double-blind, placebo-controlled, discontinuation trial enrolling 30 patients diagnosed with LEMS at sites in the U.S. and Europe. Catalyst anticipates that it will be adding up to 20 additional sites in the U.S., Europe, Canada and South America. Catalyst expects to complete enrollment in the trial by the end of the fourth quarter of 2013 and to announce top line data from the trial during the second quarter of 2014.  Full Article

UPDATE 1-Catalyst Pharma's lead drug succeeds in late-stage study

Sept 29 - Catalyst Pharmaceutical Partners Inc said its lead drug was found superior in treating symptoms associated with a rare autoimmune disorder, compared with a placebo.

Search Stocks